Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Dec;98(4):1091–1100. doi: 10.1111/j.1476-5381.1989.tb12652.x

Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase.

T Asano 1, T Suzuki 1, M Tsuchiya 1, S Satoh 1, I Ikegaki 1, M Shibuya 1, Y Suzuki 1, H Hidaka 1
PMCID: PMC1854800  PMID: 2611484

Abstract

The in vitro and in vivo vasorelaxant effects of HA1077, 1-(5-isoquinolinesulphonyl)-homopiperazine HCl, a novel vasodilator were examined. The inhibitory effects of HA1077 on contractile responses to various agonists were examined on strips of rabbit aorta. The concentration-response curves to 5-hydroxytryptamine, prostaglandin F2alpha, histamine, angiotensin II, noradrenaline and dopamine were concentration-dependently shifted to the right in the presence of HA1077 (0.3-3.0 microM). The in vivo vasodilator effects of HA1077 were examined in the constant-pressure autoperfused coronary vascular bed of dogs. Intra-coronary administration of HA1077 (3-30 micrograms per dog) dose-dependently increased coronary blood flow (CBF), with no effect on mean blood pressure (MBP) or heart rate (HR). Intra-coronary infusion of atropine, propranolol or diphenhydramine did not modify the in vivo coronary vasodilator response to HA1077. To determine the flow profile for HA1077 in dogs, blood flow in four vascular beds was measured, by use of noncannulating electromagnetic flow probes. HA1077 (0.01-0.3 mg kg-1, i.v.) dose-dependently decreased MBP and increased vertebral blood flow (VBF), CBF, renal blood flow (RBF) and femoral blood flow (FBF). A haemodynamic analysis showed that continuous i.v. infusion of HA1077 (0.01 and 0.033 mg kg-1min-1) dose-dependently decreased peripheral vascular resistance and increased cardiac output. There were no significant changes in right atrial pressure, dP/dt or ventricular minute work. The effects of HA1077 on various enzymes considered to be related to the regulation of smooth muscle contraction were examined. HA1077 had little effect on cyclic nucleotide phosphodiesterases, yet it potently inhibited protein kinases such as cyclic nucleotide dependent protein kinases and Ca2+/calmodulin dependent myosin light chain kinase. The present study demonstrates that HA1077 is a novel type of arterial vasodilator.

Full text

PDF
1091

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelstein R. S., Eisenberg E. Regulation and kinetics of the actin-myosin-ATP interaction. Annu Rev Biochem. 1980;49:921–956. doi: 10.1146/annurev.bi.49.070180.004421. [DOI] [PubMed] [Google Scholar]
  2. Adelstein R. S., Klee C. B. Purification and characterization of smooth muscle myosin light chain kinase. J Biol Chem. 1981 Jul 25;256(14):7501–7509. [PubMed] [Google Scholar]
  3. Allen G. S., Bahr A. L. Cerebral arterial spasm: part 10. Reversal of acute and chronic spasm in dogs with orally administered nifedipine. Neurosurgery. 1979 Jan;4(1):43–47. doi: 10.1227/00006123-197901000-00008. [DOI] [PubMed] [Google Scholar]
  4. Asano T., Hidaka H. Intracellular Ca++ antagonist, HA1004: pharmacological properties different from those of nicardipine. J Pharmacol Exp Ther. 1985 May;233(2):454–458. [PubMed] [Google Scholar]
  5. Asano T., Hidaka H. Vasodilatory action of HA1004 [N-(2-guanidinoethyl)-5-isoquinolinesulfonamide], a novel calcium antagonist with no effect on cardiac function. J Pharmacol Exp Ther. 1984 Oct;231(1):141–145. [PubMed] [Google Scholar]
  6. Asano T., Ikegaki I., Satoh S., Suzuki Y., Shibuya M., Takayasu M., Hidaka H. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther. 1987 Jun;241(3):1033–1040. [PubMed] [Google Scholar]
  7. Beavo J. A., Bechtel P. J., Krebs E. G. Preparation of homogeneous cyclic AMP-dependent protein kinase(s) and its subunits from rabbit skeletal muscle. Methods Enzymol. 1974;38:299–308. doi: 10.1016/0076-6879(74)38046-9. [DOI] [PubMed] [Google Scholar]
  8. Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P., Middlemiss D. N., Mylecharane E. J., Richardson B. P., Saxena P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986 Jun;25(6):563–576. doi: 10.1016/0028-3908(86)90207-8. [DOI] [PubMed] [Google Scholar]
  9. EBASHI S., EBASHI F. A NEW PROTEIN COMPONENT PARTICIPATING IN THE SUPERPRECIPITATION OF MYOSIN B. J Biochem. 1964 Jun;55:604–613. doi: 10.1093/oxfordjournals.jbchem.a127933. [DOI] [PubMed] [Google Scholar]
  10. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
  11. Gioia A. E., White R. P., Bakhtian B., Robertson J. T. Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm. J Neurosurg. 1985 May;62(5):721–728. doi: 10.3171/jns.1985.62.5.0721. [DOI] [PubMed] [Google Scholar]
  12. Hidaka H., Asano M., Iwadare S., Matsumoto I., Totsuka T., Aoki N. A novel vascular relaxing agent, N-(6--aminohexyl)-5-chloro-1-naphthalensulfonamide which affects vascular smooth muscle actomyosin. J Pharmacol Exp Ther. 1978 Oct;207(1):8–15. [PubMed] [Google Scholar]
  13. Hidaka H., Shibuya M. A new assay of cyclic nucleotide phosphodiesterase; its application to human serum. Biochem Med. 1974 Aug;10(4):301–311. doi: 10.1016/0006-2944(74)90033-7. [DOI] [PubMed] [Google Scholar]
  14. Hof R. P. Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem. Br J Pharmacol. 1983 Feb;78(2):375–394. doi: 10.1111/j.1476-5381.1983.tb09403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kuo J. F., Greengard P. Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adenosine 3',5'-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom. Proc Natl Acad Sci U S A. 1969 Dec;64(4):1349–1355. doi: 10.1073/pnas.64.4.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kuo J. F., Greengard P. Purification and characterization of cyclic GMP-dependent protein kinases. Methods Enzymol. 1974;38:329–350. doi: 10.1016/0076-6879(74)38050-0. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Perrie W. T., Perry S. V. An electrophoretic study of the low-molecular-weight components of myosin. Biochem J. 1970 Aug;119(1):31–38. doi: 10.1042/bj1190031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sasaki Y., Sasaki Y., Kanno K., Hidaka H. Disorganization by calcium antagonists of actin microfilament in aortic smooth muscle cells. Am J Physiol. 1987 Jul;253(1 Pt 1):C71–C78. doi: 10.1152/ajpcell.1987.253.1.C71. [DOI] [PubMed] [Google Scholar]
  20. Takayasu M., Suzuki Y., Shibuya M., Asano T., Kanamori M., Okada T., Kageyama N., Hidaka H. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg. 1986 Jul;65(1):80–85. doi: 10.3171/jns.1986.65.1.0080. [DOI] [PubMed] [Google Scholar]
  21. Tanaka T., Naka M., Hidaka H. Activation of myosin light chain kinase by trypsin. Biochem Biophys Res Commun. 1980 Jan 15;92(1):313–318. doi: 10.1016/0006-291x(80)91554-5. [DOI] [PubMed] [Google Scholar]
  22. VAN ROSSUM J. M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther. 1963;143:299–330. [PubMed] [Google Scholar]
  23. Varsos V. G., Liszczak T. M., Han D. H., Kistler J. P., Vielma J., Black P. M., Heros R. C., Zervas N. T. Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a "two-hemorrhage" canine model. J Neurosurg. 1983 Jan;58(1):11–17. doi: 10.3171/jns.1983.58.1.0011. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES